There is no consensus regarding the preferred dosage of aspirin in patients with atherosclerotic cardiovascular disease (ASCVD) and this has led to variability in prescribing patterns. This is likely due to the lack of head-to-head trials evaluating different aspirin doses and data weighing the clinical benefits and adverse effects experienced with aspirin. Until now?
Guest Authors: Ivy Nwogu, PharmD and Megan Supple, PharmD, BCACP, CPP
Music by Good Talk